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Abstract
Background: Endometriosis is a chronic and underdiagnosed disease which affects 5–10% of women of
childbearing age and is characterized by growth of endometrial tissue outside of the uterus, most often in the
peritoneal cavity. Delay in diagnosis is a major problem for management of this disorder, and treatment is often
not initiated until the disease has progressed for many years. Although the exact etiology of endometriosis remains
unknown, retrograde menstruation is recognized as a common underlying factor leading to the deposit of
menstrual effluent (ME) into the peritoneal cavity. Differences in the cellular biology and genetics of the cells within
ME are therefore likely to explain why endometriosis develops in only a subset of women.
Methods: Patients with and without endometriosis were consented to provide ME. ME was analyzed by flow
cytometry for CD45- and CD45+ cell populations or used to isolate stromal fibroblast cells. ME-derived stromal
fibroblast cells were assessed using decidualization assays following the addition of cAMP and IGFBP-1
concentrations in the culture supernatants were measured by ELISA. In addition, RNA was collected and analyzed
by RNA-Seq and qPCR for markers of decidualization and to identify differentially expressed genes in ME-derived
stromal fibroblast cells obtained from controls and subjects with endometriosis (±cAMP).
Results: Flow cytometry analysis of cell subsets within the CD45+ fraction of ME revealed a significant decrease in
the number of uterine NK cells in endometriosis patients compared with controls (p < 0.01). No other significant
differences within either the CD45+ or CD45- cell populations were observed. Most strikingly, ME-derived stromal
fibroblast cells cultured from endometriosis subjects showed impaired decidualization potential compared with
controls. Highly significant differences in decidualization response were detected by measuring IGFBP-1 production
at multiple time points after cAMP stimulation (p = 0.0025 at 6 h; p = 0.0045 at 24 h; p = 0.0125 at 48 h). RNA-Seq
and qPCR analyses were used to identify genes differentially expressed by ME-derived stromal fibroblast cells
obtained from endometriosis and control subjects.
Conclusions: Menstrual effluent can be useful for investigating the pathobiology of endometriosis and for
developing a non-invasive diagnostic for endometriosis which may lead to earlier and more effective treatments for
this common disorder.
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Background
Endometriosis is a chronic disease characterized by the
growth of endometrial-like tissue outside of the uterus.
It affects 5 to 10% of women globally (Giudice, 2010a).
This condition is defined clinically by its potential to
cause pelvic pain, dysmenorrhea, and infertility (Giudice,
2010a). Annually endometriosis costs in the United
States have been estimated to be as high as $50 billion
due to medical expenses, loss of worker productivity,
and both social and personal burdens (Simoens et al.,
2012). One of the most challenging problems of endometriosis is the prolonged time between disease onset
and definitive diagnosis by laparoscopic surgery, which
is approximately 7 to 10 years (Hadfield et al., 1996).
This delay in diagnosis and early treatment is caused, in
part, by the lack of non-invasive diagnostic tests for
endometriosis (Ballard et al., 2006; Giudice, 2010b).
Although the causes of endometriosis are not completely understood, one commonly accepted theory suggests that “retrograde menstruation” (the flow of
menstrual effluent (ME) through the fallopian tubes into
the peritoneal cavity) is a major contributing factor.
Retrograde menstruation occurs in almost all women
(Halme et al., 1984) and therefore other factors must
contribute to the development of endometriosis. In this
context, a key characteristic of ME is the presence of
mesenchymal stem cells (MSCs) and stromal fibroblast
cells (SFCs), which are phenotypically similar (Denu et
al., 2016; Haniffa et al., 2009; Hematti, 2012; Ulrich et
al., 2012), and are found within endometriosis lesions
(Figueira et al., 2011) and eutopic endometrium (Barragan
et al., 2016; Gargett, 2006; Masuda et al., 2010; Gargett,
2007; Fazleabas et al., 2002). MSCs and SFCs can be readily
grown in culture and exhibit immunomodulatory and angiogenic properties, making them a potential therapeutic or
regenerative resource for a variety of conditions, such as
cardiac ischemia, limb ischemia, stroke, and lung injury
(Zhang et al., 2013; Meng et al., 2007; Vu et al., 2015;
Borlongan et al., 2010; Rodrigues et al., 2016).
Previous studies report that SFCs isolated and cultured
from endometrial biopsies have the capacity to decidualize (Barragan et al., 2016). Decidualization is a normal
process within the mid-secretory phase during which
endometrial stromal cells differentiate into specialized
secretory decidual cells required for successful embryo
implantation and placental development (Gellersen &
Brosens, 2014; Dunn et al., 2003; Ramathal et al., 2010).
Giudice and colleagues have clearly shown that SFCs derived from endometrial biopsies obtained from patients
with endometriosis display impaired decidualization ex
vivo when compared to endometrial biopsy-derived
SFCs obtained from control subjects (Barragan et al.,
2016). Thus, we postulated that ME-derived SFCs may
offer a non-invasive resource for the early diagnosis of
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endometriosis based on their phenotypic differences and
decidualization capacity. In addition, we explored
whether other phenotypic characteristics of ME-derived
cells could be informative for diagnosing and better understanding the pathobiology of endometriosis, as well
as other reproductive disorders. To enable these goals
we established a protocol for the collection and transport of ME for investigative studies.

Methods
Subject recruitment and enrollment

Endometriosis subjects were recruited through the
Research OutSmarts Endometriosis (ROSE) study
(https://www.feinsteininstitute.org/rose-research-outsmartsendometriosis/; IRB#13-376A) and control subjects were
recruited from the Genotype and Phenotype (GaP) registry
(http://www.feinsteininstitute.org/robert-s-boas-center-forgenomics-and-human-genetics/gap-registry/; IRB#13-627A);
both studies were approved by the Institutional Review
Board (IRB) of Northwell Health. Briefly, women of reproductive age who were not pregnant or breast-feeding, did
not use an internal birth control device (e.g. IUD) and
were menstruating and willing to provide ME sample(s)
were recruited and consented. Women who reported the
diagnosis of endometriosis, as determined by laparoscopic
surgery and were at least one year post-op following endometrial lesion removal, were recruited via the ROSE study
(22 to 43 years old). Control subjects who self-reported no
history suggestive of a diagnosis of endometriosis were recruited through the GaP registry (21 to 47 years old). For
functional decidualization experiments using ME from
endometriosis patients and controls, only subjects who reported that they were not using hormonal birth control
were included.
Collection of menstrual effluent (ME)

ME was collected for approximately 6–10 h per collection on days 0, 1, or 2 of the menstrual phase, where day
0 is the first day of the menstrual cycle, using the DivaCup (a menstrual cup produced by Diva International
Inc., Ontario, Canada) as described previously (Howard
et al., 2011). ME was transferred to a sterile 50 mL conical tube containing 1 mg Normocin™ (Invivogen, San
Diego, CA) and 500 units penicillin streptomycin
(Gibco), placed in a refrigerated box and transported by
express shipment to the lab within approximately 24 h.
In pilot experiments we observed no differences in
freshly obtained ME vs. 24 h refrigerated/shipped ME,
based on cellular composition determined by flow cytometry, viability of non-CD66+ cells by flow cytometry,
or isolation/culture success of ME-derived SFCs. These
observations are consistent with those of van der Molen
and colleagues, who reported that CD45+/CD66- ME
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cells remained viable for at least 72 h post collection
(van der Molen et al., 2014).
Flow cytometry of ME and cultured SFCs

After removing the soluble fraction from whole ME following a brief centrifugation and lysis of red blood cells
with BD Pharm Lyse (BD Biosciences, Billerica, MA),
samples (from n = 8 endometriosis and n = 14 control subjects) were passed through a 35 μm cell strainer attached
to polystyrene FACS tube (Thermo Fisher Scientific,
Bridgewater, NJ). ME-cells were then pelleted and incubated with Human Fc Block (BD Biosciences) for 20 min.
After a brief wash, cells were incubated with either the
CD45+ or CD45- panels of antibodies listed in Table 1 or
Table 1 ME FACS Staining Panels
Fluorochrome

the appropriate isotype control antibodies. All cells were
subjected to Aqua live/dead viability staining (Thermo
Fisher) and then stained with antibodies in Table 1 for
30 min at 4 °C. The cells were washed twice with 1% FBS
in PBS and fixed with 3% paraformaldehyde (PFA) if not
being analyzed same day. All data were collected on the
Fortessa Flow Cytometer (BD) and analyzed using FlowJo
software (version 10.1r5; Ashland, OR).
Cultured SFCs (passage 1 from n = 7 endometriosis
and n = 7 control subjects), as described below, were
lifted with ACCUTASE™ (STEMCELL TECHNOLOGIES, Cambridge, MA) at confluence and resuspended
in Brilliant Stain Buffer (BD Biosciences) with the staining antibody panels listed in Table 2 or appropriate isotype control antibodies for 30 min at 4 °C and fixed with
2% PFA. The cells were washed twice with 1%FBS in
PBS. All data were collected on the Fortessa Flow
Cytometer (BD) and analyzed using FlowJo software
(version 10.1r5; Ashland, OR).

Antigen

Cat. No

PE

CD20

555623

FITC

CD16

302006

APC

CD56

555518

Pacific Blue

CD66b

305112

APC-Cy7

CD3

557757

PerCP-Cy5.5

CD14

562692

PE-Cy7

CD45

557748

PE

CD105

560839

PerCP-Cy5.5

CD326

347199

APC

CD73

560847

FITC

CD90

555595

APC-Cy7

CD31

563653

Table 2 ME-SFC Staining Panel

PE-Cy7

CD45

557748

Fluorochrome

Antigen

Company

Cat. No.

Aqua (AmCyan)

Live/Dead

L34966

PERCP-Cy5.5

CD105

BD Pharmingen

560819

FITC

CD90

BD Pharmingen

555595

CD45+ Staining Panel

CD45- Staining Panel

CD45+ Staining Panel Isotype Controls

ME-derived stromal fibroblast cell (SFC) isolation and
culture

Whole ME (500 μL) was plated in T75 flasks in SFC
media: 10% FBS (MSC-qualified, Gibco), 1X glutamine
(Gibco), 100 units/ml penicillin-streptomycin (Gibco),
and 100 μg/ml Normocin™ in DMEM (Gibco). Flasks
were incubated at 37 °C/5%CO2 for 48–72 h in order
to isolate SFCs by adherence. After washing, adherent
cells were cultured to 80% confluence before lifting
with trypsin/EDTA and subsequently freezing stock
cells at passage 1 (p1).

PE

Mouse IgG2b, κ

555743

APC

CD73

BD Pharmingen

560847

FITC

Mouse IgG1

349041

BV421

CD140b

BD Pharmingen

564124

APC

Mouse IgG1, κ

555751

PE

SUSD2

Biolegend

327406

Pacific Blue

Mouse IgM, K

401619

BV711

CD146

BD Pharmingen

563186

APC-Cy7

Mouse IgG1, K

557873

BV786

CD45

BD Pharmingen

563716

PerCP-Cy5.5

Mouse IgG2b, K

558304

BV605

EPCAM

Biolegend

324224

PE-Cy7

Mouse IgG1

348798

PERCP-Cy5.5

Isotype

BD Pharmingen

552834

FITC

Isotype

BD Pharmingen

349041

CD45- Staining Panel Isotype controls
PE

Mouse IgG1

349043

APC

Isotype

BD Pharmingen

555751

APC

Mouse IgG1, κ

555751

BV421

Isotype

BD Pharmingen

562439

PerCP-Cy5.5

Mouse IgG1, κ

552834

PE

Isotype

Biolegend

400114

FITC

Mouse IgG1

349041

BV711

Isotype

BD Pharmingen

563044

APC-Cy7

Mouse IgG1, K

557873

BV786

Isotype

BD Pharmingen

564230

PE-Cy7

Mouse IgG1

348798

BV605

Isotype

Biolegend

400350
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Decidualization assays using ME-derived SFCs

Cryopreserved ME-derived SFCs (p1) were defrosted
and plated in 24-well plates in SFC media; at confluence
SFCs (p2) were incubated at 37 °C/5%CO2 in decidualization media (2% FBS MSC-qualified, 1X glutamine,
100 units/ml penicillin-streptomycin, and 100μg/ml
Normocin™ in Phenol Red Free DMEM with either
0.5 mM 8-Bromoadenosine 3′,5′-cyclic monophosphate
(cAMP, Sigma-Aldrich, St. Louis, MO) ± 10 nM 17-beta
estradiol (E2) (Tocris, Minneapolis, MN) and 1 μM
medroxyprogesterone acetate (MPA, Sigma-Aldrich) or
vehicle (PBS for studies with cAMP alone or 0.01% ethanol for studies with cAMP + E2 + MPA). Cells were
stimulated for 6 h, 24 h, and 48 h, at which point supernatants and cell lysates were collected from each well for
the time course experiment. Supernatants were analyzed
for IGFBP-1 concentrations by ELISA (Duoset, R&D
Systems, Minneapolis, MN) and results were normalized
to cell lysate protein concentrations using the Bio-Rad
Protein Assay Kit (Bio-Rad, Hercules, CA).
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Statistical analyses
Flow cytometry analyses of the cellular composition of
whole ME

All analyses were carried out separately for each cell
population. For each cell population within the CD45+
and CD45- subsets, a linear mixed model was used to
examine the association between group and that population using SAS Version 9.4 (SAS Institute Inc., Cary,
NC). The mixed models approach was used to account
for the hierarchical nature of the data (namely, multiple
samples from one or more cycles within a subject). Time
of day (evening, overnight) and day of cycle collection
was started (0, 1–2) were included as covariates in the
model to adjust for any effects they might have on cell
population.
Transformations (namely log or arcsine square root)
were used to better meet the assumptions of the linear
model. However, as the results obtained from the models
using transformed data did not differ qualitatively from
those using the raw data, results using the raw data are
presented for ease of interpretation.

RNA-Seq and qPCR

Total cellular RNA was isolated following stimulation of
ME-derived SFCs (collected from n = 7 endometriosis
subjects and n = 7 control subjects) with either 0.5 mM
cAMP or vehicle for 6 h, as described above using the
mirVana™ miRNA Isolation Kit and treated with the
DNA-free™ kit (Ambion) to remove DNA (Ambion). Supernatants were also collected and analyzed for IGFPB-1
by ELISA, as described above. RNA sequencing was performed using the Illumina mRNA TrueSeq Stranded
method. The raw image files from the NextSeq sequencer were de-multiplexed and converted to FASTQ files
using Illumina’s bcl2fastq BaseSpace App. The FASTQ
files were aligned to the hg19 human reference genome
from GENCODE using the STAR2 aligner and the
digital gene counts quantified using HTSeq. The differential expression analysis was done using DESeq2.
ALDH1A1 expression was assessed by qPCR using
RNA collected from ME-SFCs following 6 h treatment
with vehicle or 0.5 mM cAMP (n = 7 endometriosis subjects and n = 7 control subjects). qPCR was performed
with probes and primers designed using ProbeFinder online software (left primer: ccaaagacattgataaagccataa; right
primer: cacgccatagcaattcacc) and probe #82 of the Universal ProbeLibrary (Roche, Basel, Switzerland). qPCR,
using GAPDH as control, was performed on the Roche
LightCycler 480 qPCR machine using the following conditions: 2 min at 50 °C, 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and 1 min at 60 °C. Relative
changes in gene expression were calculated as foldchanges using the comparative Ct (ΔΔCt method) and
statistical analysis was done through the Mann-Whitney
Test (Cikos & Koppel, 2009).

SFC Decidualization time course

To determine differences in IGBFP-1 protein levels between treatments and cases/controls, a Bayesian hierarchical model was implemented. The data consists of
normalized measurements of IGFBP-1 protein levels of 7
endometriosis cases and 7 controls, across four different
treatments (cAMP, vehicle for cAMP alone, ethanol vehicle, and cAMP+MPA + E2). Each treatment has protein measurements for all the subjects at three different
time points (6 h, 24 h, and 48 h).
The response variable - protein levels - was logtransformed in order to adjust for heteroscedasticity in
the original scale and the covariate included was an indicator variable for whether a subject was a case or a control, and indexed according to the treatment and time
period in which the subjects were analyzed. For the hierarchical structure, subjects were nested within treatments at each time point. A model assuming normally
distributed residuals estimated both the mean protein
content at each level; a group parameter was used to estimate the effect of being in the case/control group. The
posterior probability of the group effect being zero was
assessed and is summarized in Additional file 1:
Table S1. Data was arranged using R (version 3.3.2)
and the model was implemented in Stan (version
2.16.2) using the R interface. The model is estimated
using the No-U-Turn sampler algorithm (Hoffman &
Gelman, 2014) a version of Hamiltonian Monte Carlo
(Neal, 1994). Once posterior draws were estimated,
the model was simulated for each draw, resulting in
the generated quantities. All other data were analyzed using the Mann-Whitney test.
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Results
ME contains CD45+ and CD45- cell populations and ME
collected from endometriosis subjects has fewer uterine
NK cells

Flow cytometric analysis was performed on fresh ME
collected from control and endometriosis subjects for
both CD45+ leukocyte populations and CD45- cell populations (Fig. 1a, b). After gating out dead cells, ME is
mainly comprised of CD45+ cells, with the CD45- cell
populations contributing on average 1.6 ± 0.3% for control subjects and 1.9 ± 0.5% for endometriosis subjects
(Additional file 1: Table S1). The CD45+ population includes granulocytes, monocytes, T cells, B cells, and natural killer (NK) cells. The vast majority of NK cells
found in ME are uterine NK (uNK) cells based on their
lack of CD16 expression and high expression of CD56
(see Fig. 1a). Depending on the ME sample the CD66b +
population made up the majority of the CD45+
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population, with 55.6 ± 5.1% for control subjects and
56.7 ± 6.5% for endometriosis subjects (Additional file 1:
Table S1). The CD66b + granulocyte population was
variable between subjects and samples collected, possibly
due to the poor viability of granulocytes. In order to account for the variability of the granulocyte population
between samples, the data was normalized by adjusting
the cell count of the population of interest (monocytes,
T cells, B cells, or uNK cells) to the cell count of the
CD45+ CD66b- population. Although, no significant differences between ME collected from endometriosis vs.
control subjects were found for granulocytes, monocytes, T cells, or B cells, there were significantly less
uNK cells (p = 0.01) in ME collected from endometriosis
subjects compared to control subjects (Fig. 1c).
The CD45- populations analyzed included epithelial
cells, endothelial cells, and stromal fibroblast cells
(SFCs) (Fig. 1b). There were no significant differences

Fig. 1 Flow Cytometric analysis of ME from endometriosis and control subjects CD45+ (n = 14 control, n = 8 endometriosis) (a) and CD45- (n = 14
control, n = 6 endometriosis) (b) flow cytometry staining scheme for ME. Box plots showing the cellular composition CD45+ subsets (CD66b +
granulocytes [Granulo], CD14+ monocytes [Mono], CD20+ B cells, CD3+ T cells, and CD56+ uterine natural killer (uNK) cells) (c) and CD45- subsets
(CD45-, CD326+ epithelial cells [Epith], CD31+ endothelial cells [Endo], CD326-/CD31- cells, and CD73+/CD90+/CD105+ [SFCs] (d) found in menstrual
effluent from women with and without endometriosis. The CD66b + and CD66b- populations were normalized to the CD45+ population cell counts
and the CD14+ Mono, CD20+ B Cells, CD3+ T cells, and CD56+ uNK cell populations were normalized to CD66b-population cell counts. The Epith,
Endo, CD326-/CD31- cells, and SFC populations were normalized to the CD45- population cell counts. Data are shown as box plots depicting the
median and interquartile ranges for each cell subset; significance for uNK cells **p = 0.01 (c)
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found in the percentages of epithelial cells (CD31-,
CD326+/EPCAM) or endothelial cells (CD31+, CD326-)
among total CD45- cells when comparing ME obtained
from control to endometriosis subjects (Fig. 1d). The
SFC population was defined as: CD45-/CD326-/CD31-/
CD90+/CD105+/CD73+ (Fig. 1b, d) and no significant
differences in the SFC populations were found when
comparing fresh ME obtained from endometriosis subjects to control subjects (Fig. 1d).
Next, we assessed cultured ME-derived SFCs (p1) for
surface markers by flow cytometry. Cultured SFCs were
positive for CD105, CD90, and CD73 and negative for
CD45 (Fig. 2). In addition, ME-SFCs expressed the fibroblast marker CD140b (Fig. 2). No significant differences
in CD90 or CD73 expression (based on geometric
mean fluorescence intensity, gMFI) were found when
comparing cultured ME-SFCs derived from endometriosis to control subjects. However, CD105 expression
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(gMFI) was significantly higher on control subject
SFCs than endometriosis subject SFCs (p < 0.05) (Fig. 2
lower right panel).
Cultured ME-derived SFCs from endometriosis subjects
have reduced decidualization capacity

It has been reported that endometrial stromal cells cultured from endometrial biopsies and hysterectomy samples obtained from endometriosis subjects have a
reduced potential to decidualize when compared to
those obtained from control subjects (Barragan et al.,
2016; Klemmt et al., 2006). In order to investigate
whether similar differences are observed using cultured
SFCs derived from ME, we performed in vitro decidualization assays at 3 different time points: 6 h, 24 h, and
48 h post 0.5 mM cAMP vs. vehicle using passage 2
SFCs obtained from control and endometriosis subjects.
Decidualization was assessed by measuring IGFBP-1

Fig. 2 Cultured ME-derived SFCs express CD73, CD90, CD105, and CD140b but not CD45 or CD326. Flow cytometry gating of cultured ME-derived
SFCs to show CD45-/CD326- population (upper panel). The CD45- population of ME derived SFCs from endometriosis (n = 7) and control (n = 7)
subjects at passage 1 were further analyzed by flow cytometry for CD90, CD73, CD140b, and CD105 expression (lower panel). CD105 expression
is lower on endometriosis-SFCs when compared to control subject-SFCs (lower right panel). Data are shown as geometric mean fluorescence intensity
(gMFI), for each subject’s SFC culture and the horizontal lines are the group means, *p = 0.03
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concentrations in the culture supernatants by ELISA. As
expected, stimulation with cAMP induced decidualization of ME-SFCs, as determined by enhanced IGFBP-1
production, which was detectable at 6 h and continued
to increase through 48 h (Fig. 3). Significantly less
IGFBP-1 was produced following both vehicle-treatment
and cAMP-treatment at all three time points by MESFCs obtained from endometriosis subjects when compared to control subjects (p < 0.05) (Fig. 3). Similarly, the
addition of MPA and E2 to cAMP induced decidualization, as determined by IGFBP-1 levels. ME-SFCs obtained
from endometriosis subjects produced significantly less
IGFBP-1 following stimulation when compared to control
ME-SFCs (Additional file 2: Figure S1). Additionally, individual subject’s ME-SFCs that produce high or low
amounts of IGFBP-1 do so consistently across all threetime points (Additional file 3: Figure S2).
Gene expression analysis of cultured ME-SFCs derived
from endometriosis subjects and controls

We performed RNA-Seq on cultured ME-SFCs isolated
from a small number of endometriosis (n = 3) and control (n = 3) subjects following cAMP or vehicletreatment for 6 h (Fig. 4a, b). Many of the genes previously reported to be increased during decidualization
were also increased in the decidualizing SFCs from both
endometriosis subjects and controls (Fig. 4b; Additional
file 1: Table S2). These genes included IGFBP1, SST,
PRL, BCL2L11, WNT5A, and FOXO1 (Additional file 1:
Table S2). When comparing ME-SFCs obtained from
endometriosis and control subjects, we observed differentially regulated genes in both vehicle-treated and
cAMP-treated cultures. A volcano plot shows the top
differentially regulated genes for both endometriosis and
control subjects in the cAMP-treated and vehicle-
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treated groups (Fig. 4a, b). The most striking difference
between the control and endometriosis SFCs was the
high expression of ALDH1A1 (encoding aldehyde dehydrogenase 1 family member A1) in control SFCs, regardless of treatment. We confirmed these findings
using qPCR for a larger number of ME-SFCs (n = 7 subjects per group), as shown in Fig. 5. These differences
were unaffected by stimulation with cAMP (Fig. 5). Although the relative lack of expression in the endometriosis SFCs remained significant, there was an outlier in
the endometriosis group which was not readily explained
by any particular subject characteristic.

Discussion
Almost all women experience retrograde menstruation,
a process by which menstrual effluent (ME) shed from
the endometrium is effluxed through the fallopian tubes
into the peritoneal cavity, where it implants on the serosal surface (Halme et al., 1984). Evidence that effluxed
ME is likely to be a major source of cells responsible for
the formation of peritoneal endometriosis lesions in patients is supported by studies in baboons showing that
consecutive intraperitoneal injections of shed menses results in endometriosis lesions in the peritoneal cavity
and by the presence of spontaneous endometriosis in
menstruating non-human primates, along with the
complete absence of endometriosis in non-menstruating
mammals (Fazleabas et al., 2002; D'Hooghe et al., 1994;
D'Hooghe et al., 2009). Our findings suggest that analysis of ME shed from the endometrium can be harnessed to investigate the pathobiology of endometriosis
and to develop early, non-invasive diagnostic methods
for endometriosis.
Individual differences in the cellular content of ME
offer a potential tool for investigating why only 5–10%

Fig. 3 ME-derived SFCs obtained from endometriosis subjects exhibit reduced decidualization capacity. Time course of IGFBP-1 secretion by vehicle
(Veh) and cAMP treated (0.5 mM) ME-derived SFCs isolated from endometriosis and control subjects (n = 7 control, n = 7 endometriosis). Data are
shown as IGFBP-1 values for each subject’s SFC culture and the horizontal lines represent group means. ** posterior probabilities (Pr) < 0.01 *Pr < 0.05.
Statistics were performed on log transformed data, as described in the methods, see Additional file 1: Table S3)
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Fig. 4 Numerous genes are differentially expressed when comparing vehicle-treated and cAMP-treated SFCs obtained from subjects with endometriosis
vs. controls. Volcano plots of genes differentially regulated between endometriosis and control subjects in the vehicle-treated group (a) and the
cAMP-treated group (b) (n = 3 control, n = 3 endometriosis for A and B)

Fig. 5 SFCs from endometriosis subjects exhibit reduced ALDH1A1
expression. ALDH1A1 expression by vehicle and cAMP-treated SFC
obtained from subjects with and without endometriosis (n = 7 subjects
per group) was confirmed by qPCR. Data are shown as relative gene
expression (fold-change) for each subject’s SFC culture; horizontal lines
represent group medians and vertical lines represent interquartile
ranges, *p < 0.05, calculated using Mann Whitney Test

of females actually develop endometriosis, given the ubiquity of retrograde menstruation. A relatively small
number of published studies have analyzed the composition of ME, comparing it to that of peripheral blood;
these studies primarily focused on phenotyping the
CD45+ cell populations (van der Molen et al., 2014;
Hosseini et al., 2015). Consistent with previous reports we found that ME is mainly comprised of
CD66b + granulocytes, followed by CD3+ lymphocytes,
CD56bright uNK cells, and then CD14+ monocytes
and CD20+ B cells (van der Molen et al., 2014;
Hosseini et al., 2015). The variability that we observed
among the various subpopulations of CD45+ cells
(Fig. 1a and c) was similar to that previously reported (van der Molen et al., 2014; Hosseini et al.,
2015). Neither of these previous studies compared
ME obtained from endometriosis subjects to controls.
Despite the variability in the cellular composition of
ME, we found that endometriosis subjects had significantly lower percentages of uNK cells when compared
to controls (Fig. 1c). uNK cells are CD56bright/CD16-,
unlike peripheral blood NK cells which are CD56dim/
CD16+. uNK cells are proposed to play an important
role in endometrial vascularization and decidualization, as well as the development of decidualizationrelated infertility observed in women with endometriosis (Gellersen & Brosens, 2014).
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Decidualization is a process in which endometrial stromal fibroblast-like cells differentiate into specialized
secretory decidual cells during the mid-secretory phase
to prepare the uterus for implantation and placental development (Gellersen & Brosens, 2014; Dunn et al.,
2003; Ramathal et al., 2010). A very recent study reveals
that uNK cells target and eliminate senescent endometrial stromal fibroblast-like cells, and this may be an important process for successful decidualization (Brighton
et al., 2017). A reduction in uNK cells found in ME collected from subjects with endometriosis may be linked
to the impaired elimination of senescent uterine cells
that compromises the decidualization process – which is
implicated in the infertility observed in patients with
endometriosis. Future studies will focus on more detailed analyses of the NK cell population found in ME
collected from controls and subjects with endometriosis.
Several previous studies have highlighted the regenerative capacity of ME-derived CD45- mesenchymal and
stromal cells (Zhang et al., 2013; Meng et al., 2007; Vu
et al., 2015; Borlongan et al., 2010; Rodrigues et al.,
2016). The CD45- cell fraction contributes to approximately 1.5–2% of the total non-RBC portion of ME. The
majority of these cells were not endothelial or epithelial
cells, but rather CD73/CD90/CD105 expressing cells.
We observed no significant differences in these subpopulations of CD45- cells found in ME collected from
endometriosis subjects vs. controls (Fig. 1d). However,
we did not include a distinction between the endometrial MSC and SFC populations in the ME; this could be
addressed in future studies using CD146/CD140b
markers, as described by studies of endometrial biopsies
(Barragan et al., 2016). Among cultured SFCs, we did
observe a lower level of expression of CD105 (endoglin)
in those isolated from ME collection from endometriosis
patients. CD105 is an auxiliary receptor for the TGFβ receptor complex and regulates the binding of various ligands, including TGFβ1 and TGFβ3, as well as BMP-2
and -7 (Guerrero-Esteo et al., 2002). Differences in
CD105 expression between endometriosis patients and
controls have been reported by others (Hayrabedyan et
al., 2005), but these studies focused on CD105 expression by the microvasculature of eutopic endometrium
and ovarian endometriosis and not non-vascular CD105
expression. This finding will need to be explored further
in future analyses.
A major innovation of this study over prior studies
profiling the cellular composition of ME is that we included functional assessment of the SFCs (of the CD45fraction). Taking advantage of the fact that defects in
stromal cell decidualization (obtained from invasive
uterine biopsies) have been reported in the setting of
endometriosis (Klemmt et al., 2006; Aghajanova et al.,
2011; Yin et al., 2012), we compared ME-derived SFCs
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obtained from controls and endometriosis subjects for
their decidualization response using cAMP. We demonstrate that a reduced decidualization response by MEderived SFCs is clearly associated with endometriosis, as
shown in Fig. 3. In fact, ME-SFCs obtained from women
with endometriosis exhibit significantly reduced IGFBP-1
expression in the absence of decidualization stimuli
(Fig. 3). These differences persist over time in culture and
likely reflect a quantitative impairment in decidualization
capacity. This difference is observed with cAMP alone, as
well as when decidualization is induced in the presence of
cAMP + MPA + E2 (Additional file 2: Figure S1).
Interestingly, we have occasionally observed impaired
decidualization capacity in control subjects’ SFCs (Fig.
3). This may reflect the presence of asymptomatic endometriosis in these individuals. Alternatively, genetic variation may influence the decidualization response in the
absence of endometriosis. Genetic differences play a significant role in risk for endometriosis; a recent metaanalysis of over 170,000 endometriosis patients and almost 200,000 controls revealed 14 genetic regions of
interest, including WNT4, GREB1, IL1A, and CDKN2B
(Sapkota et al., 2017). The examination of phenotypic diversity of ME may also shed light on the mechanisms of
genetic predisposition (Rahmioglu et al., 2015). In this
context it will be of interest to examine decidualization
capacity in control subjects who carry genetic risk alleles
for endometriosis (Rahmioglu et al., 2015). For example,
WNT4 plays a direct role in the decidualization response, and WNT4 risk haplotypes for endometriosis
have been reported to contain an estrogen response
element that may regulate its expression (Zhang et al.,
2017). Over the last decade, we have established a large
registry of normal controls (GaP) with GWAS genotype
data and subjects can be recalled for phenotypic studies
based on a genotype of interest (Gregersen, 2009; Gregersen et al., 2015). This offers the possibility of examining a variety of endometriosis risk haplotypes with
regard to their impact on decidualization capacity in
various populations. The use of ME as a source of SFCs
makes such studies possible without the need for invasive procedures. Thus, we believe that one of the major
benefits of this study is to open up the possibility of carrying out population-based genotype-phenotype studies
that are relevant to better understanding the underlying
pathogenesis of endometriosis.
Another potential benefit of studying ME, which can be
sampled throughout menstruation and monthly, is that it
may lead to the development of early, non-invasive diagnostic methods. The long delay between symptom onset
and diagnosis in this disease is well established (Hadfield
et al., 1996; Arruda et al., 2003), and no laboratory diagnostic makers have emerged to replace, or even guide, the
performance of the gold standard of laparoscopic surgery
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and histologic confirmation. The expression of BCL6 (Evans-Hoeker et al., 2016) has been reported to be altered in
secretory phase endometrial biopsies and may be useful
diagnostically, but this approach will require invasive biopsy procedures. Other possible diagnostic markers for
endometriosis include CA-125 (Hirsch et al., 2017), VEGF,
microRNAs, immunologic markers, and soluble ICAM
levels (Acimovic et al., 2016; Vodolazkaia et al., 2016;
Gagné et al., 2003; Matalliotakis et al., 2001; Kuessel et al.,
2017; Mosbah et al., 2016; Bohler et al., 2007; DrosdzolCop et al., 2012; Wu et al., 2015); however, none of these
can identify endometriosis patients with both high sensitivity and specificity. It is clear that the need for a noninvasive diagnostic marker or method remains, and it
would appear that the analysis of ME may offer a path to
develop such tests. As discussed above, our findings of a
reduced uNK cell population in the ME of endometriosis
subjects may not be specific for endometriosis, and may
simply reflect the relative lack of decidualization in these
subjects, as decidualization is accompanied by extensive
uNK infiltration during the mid-luteal phase under normal conditions (Gellersen & Brosens, 2014). Future studies are warranted to investigate the mechanism underlying
this difference.
Although we observed significant decidualization by
ME-derived SFCs (based on IGFBP-1 protein release)
within 6 h of cAMP simulation, a diagnostic based on
culturing ME-derived stromal cell populations to assess
decidualization capacity is not practical for routine clinical use. We believe that a direct assessment of freshly
isolated stromal cells from ME is likely to be the most
promising approach, based on gene expression, epigenetic analysis or other phenotypic changes in these cells.
The fact that gene expression differences, such as
ALDH1A1, can be observed in unstimulated cultured
SFCs is encouraging. However, our sample size is small
and a much larger study of patients and controls is required to establish which, if any, gene expression patterns by ME-derived SFCs will have diagnostic utility.
Ideally, these studies should be done on selected, uncultured ME cells in order be consistent with a practical
diagnostic test.
This study is the first to demonstrate that uNK
cells are significantly reduced in ME obtained from
endometriosis subjects and that ME-derived SFCs
from subjects with endometriosis exhibit significantly
impaired decidualization, along with lower expression
of ALDH1A1 than controls. However, there are several limitations that need to be considered. First, the
population sizes for our experiments are small, given
the prevalence of endometriosis. In order to be
confident of our results, we collected multiple ME
samples during the first 3 days of the cycle (days 0–2
only) and over multiple cycles for several subjects for
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the phenotyping studies. We also restricted our functional assays on decidualization capacity using SFCs
collected from donors who reported no hormone use,
in case hormone use affects decidualization outcomes.
In addition, given the small number of samples analyzed by RNA-Seq, we verified our results on
ALDH1A1 using qPCR with SFCs using a larger
group of controls and affected subjects. We did not
stage our endometriosis subjects based on disease severity, in part because we did not have the confirmed,
documented data and because of our restricted sample size. However, all endometriosis diagnoses were
confirmed by laparoscopy. It is also important to note
that the stage of endometriosis does not necessarily
reflect the severity of clinical symptoms a patient presents with (Johnson et al., 2017). It is our goal to develop a diagnostic tool that identifies endometriosis
across all stages of endometriosis (particularly, during
the early stages); however, having information on the
stage of endometriosis would be useful to identify
population subsets. Finally, as discussed above, our
control group was not laparoscopically confirmed and
this may contribute to the small number of subjects
that did not ‘classify’ with the result of the controls.
Our studies demonstrate that the ready availability
of ME will permit larger studies in the future to develop non-invasive diagnostic methods for endometriosis. These studies will also enable investigation of
disease heterogeneity and mechanisms of pathogenesis. Decidualization defects may arise through many
different genetic and environmental mechanisms, and
these may suggest different approaches to therapy. Indeed it is possible that decidualization defects and
gene expression changes in eutopic endometrium may
in some cases arise as a result of the presence of
endometriosis lesions in the peritoneum, as suggested
by studies in the baboon (Fazleabas et al., 2002). In
this context it will be of interest to study ME phenotypes before and after surgical or medical treatments
and to correlate these findings with the presence or
absence of persistent infertility. ME is particularly
useful for these types of studies because it can be collected in a non-invasive manner repeatedly over several months. Finally, ME analysis may be very useful
in the general evaluation of female infertility, particularly related to decidualization, outside of endometriosis (Gellersen & Brosens, 2014).

Conclusion
In conclusion, we propose that the routine analysis of
ME phenotypes holds promise for understanding and
diagnosing endometriosis, as well as potentially other reproductive disorders. This may include the use of proteomic and metabolomic methods, as well as emerging
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technologies of single cell analysis of freshly isolated
cells. Collection using the menstrual cup has proved remarkably useful and should be able to support a variety
of such studies, although we believe there is room for
development of collection devices that may be tailored
to particular analytic questions. We hope that the studies reported here will provoke a wider interest in ME as
a clinical and research tool.
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0.5 mM cAMP+ 1 μM MPA+ 10 nM E2-treated ME-derived SFCs isolated
from endometriosis (Endo) and control subjects (n = 7 control, n = 7
endometriosis). Data are shown as IGFBP-1 values for each subject’s
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